Claim Missing Document
Check
Articles

Kadar Transthyretin Plasma pada Lanjut Usia Sarkopenia dan Non-Sarkopenia Fahrurozi, R. Ifan A.; Martini, Rose D; Mulyana, Roza; Murni, Arina W; Decroli, Eva; Miro, Saptino; Viotra, Deka; Yoga, Vesri
Jurnal Penyakit Dalam Indonesia
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Sarcopenia is a geriatric syndrome marked by an age-related decline in muscle mass, which is affected by protein intake. Transthyretin is a visceral protein used to evaluate nutritional status and acts as a positive regulator of muscle mass. This study aimed to assess the difference in plasma transthyretin levels between elderly groups with and without sarcopenia. Methods. This was an analytical observational study with a cross-sectional approach. Subjects were elderly patients who visited the Internal Medicine Polyclinic of Dr. M. Djamil Hospital Padang and met the inclusion and exclusion criteria from August to September 2024. Subjects were classified into sarcopenic and non-sarcopenic groups, followed by an examination of plasma transthyretin levels. Sarcopenia was diagnosed using bio-impedance analysis (BIA) measurement, handgrip strength with a Jamar hydraulic hand dynamometer, and physical performance with a walking speed test. Plasma transthyretin levels were measured using the enzyme-linked immunosorbent assay (ELISA) method. Comparative analysis was performed using the unpaired T-test using SPSS 29.0. Results. Among total of 46 subjects who participated in this study, the majority of elderly individuals with sarcopenia were predominantly female. The mean plasma transthyretin level in the sarcopenic elderly group was 10.9 (3.3) mg/dL, while in the non-sarcopenic elderly group was 20.3 (2.5) mg/dL. Comparative analysis demonstrated a significant difference in plasma transthyretin levels between sarcopenic and non-sarcopenic elderly individuals (p < 0.001). Plasma transthyretin levels in the sarcopenic elderly group were lower compared to the non-sarcopenic elderly group. Conclusion. There is a significant difference in plasma transthyretin levels between sarcopenic and non-sarcopenic elderly individuals.
FACTORS ASSOCIATED WITH MORTALITY OF ELDERLY PATIENTS WITH COVID-19 INFECTION AT M. DJAMIL HOSPITAL, PADANG, WEST SUMATRA, INDONESIA : COVID-19 INFECTION Mulyana, Roza; Elvira, Dwitya; Martini, Rose Dinda
INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD) Vol. 7 No. 2 (2025): INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT
Publisher : STIKes Mandala Waluya Kendari

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36566/ijhsrd/Vol7.Iss2/329

Abstract

Background: To analyze the factors influencing the mortality incidence of elderly patients with COVID-19 infection in Padang, West Sumatra, Indonesia. Methods: This is a retrospective study at M. Djamil Hospital, Padang. Data was collected from the medical records of COVID-19 patients treated during July-September 2021. Results: Of the 243 elderly patients who experienced COVID-19, the most deaths were male (58.6%) with an average age of 69.64 ± 7.74 years. Multivariate analysis showed that patients with critical-severe clinical symptoms (odds ratio (OR) 12.95; 95% confidence interval (CI) 6.66–25.19), heart disease (OR 6.94; 95% CI 1.63–29.60), respiratory rate ≥30 breaths per minute (OR 3.48; 95% CI 1.04–11.60), pulse ≥100 beats per minute (OR 2.88; 95% CI 1.03–8.04), using a ventilator or high-flow nasal cannula (OR 19.78; 95% CI 5.92–66.10), prothrombin time >13.16 second (OR 12.35; 95% CI 2.43–62.77), interleukin-6 >6 pg/mL (OR 15.19; 95%CI 2.53–91.26), and random blood glucose >199 mg/dL (OR 3.45; 95% CI 1.02–11.68) have a high risk of death. Conclusion: Elderly patients with COVID-19 infection with critical-severe clinical symptoms accompanied by heart disease, using ventilator or high-flow nasal cannula, longer prothrombin time, high level of interleukin-6, and random blood glucose have higher risk of mortality.
CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA LEADING TO LIFE-THREATENING HYPOVOLEMIC SHOCK IN CERVICAL CANCER: A CASE REPORT Nurul Fadila; Raveinal Raveinal; Fadrian Fadrian; Roza Mulyana
Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal) Vol 14, No 5 (2025): JURNAL KEDOKTERAN DIPONEGORO (DIPONEGORO MEDICAL JOURNAL)
Publisher : Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/dmj.v14i5.47148

Abstract

Hypovolemic shock due to acute hemorrhage is a life-threatening condition, particularly in cancer patients undergoing chemotherapy. Although recent studies have established protocols for managing hypovolemic shock in trauma and sepsis, the role of chemotherapy-induced thrombocytopenia in exacerbating post-procedural bleeding risks remains underexplored. This case emphasizes the clinical complexity of managing hemorrhagic shock in advanced-stage cervical cancer patients following percutaneous nephrostomy (PCN). Case Presentation: A 52-year-old female with stage IVB cervical cancer and liver metastasis presented with hypovolemic shock following PCN. She exhibited severe hematuria and chemotherapy-induced thrombocytopenia, leading to prolonged bleeding and subsequent shock. Initial management involved aggressive fluid resuscitation, blood transfusions, and correction of thrombocytopenia. Despite the challenges of managing shock in a patient with concurrent chronic kidney disease (CKD) stage IV, prompt intervention led to significant clinical improvement, stabilization of vital signs, and eventual discharge. Conclusion: This case highlights the importance of early intervention in managing hypovolemic shock in oncology patients with multiple comorbidities, including chemotherapy-induced thrombocytopenia and CKD. A multidisciplinary approach and close monitoring are crucial for improving outcomes in such high-risk patients. Further research is needed to establish tailored management protocols for this patient population.